Annovis Bio Inc stock is traded at $0.6689, with a volume of 30,867,698. It is down -44.72% in the last 24 hours and down -43.31% over the past month. Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
Previous Close:
$1.21
Open:
$0.88
24h Volume:
30,867,698
Relative Volume:
7.40
Market Cap:
$28.78M
Revenue:
-
Net Income/Loss:
-$40.92M
P/E Ratio:
-
EPS:
-$1.72
Net Cash Flow:
-$26.53M
1W Performance:
-40.81%
1M Performance:
-43.31%
6M Performance:
-72.13%
1Y Performance:
-66.39%
1-Day Range:
$0.00$0.00
1-Week Range:
$0.6161$1.40
52-Week Range:
$0.6161$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
Name
Annovis Bio IncSector
HealthcareIndustry
BiotechnologyPhone
484-875-3192Address
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS